Vascepa, approved in the U.S. to reduce triglycerides and cardiovascular events, helped Amarin generate $285.3M in net ...

Generic drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that sets up early competition to cardiovascular drug Vascepa, Amarin’s only commercial ...

Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down. Uncovering affordable breakthrough stocks under $ ...

Amarin said in a statement that this is the first drug in the class to be recommended by NICE for cardiovascular risk reduction. The final guidance is expected to be published on 20 July.

The office space at Gaysorn Amarin, with the total lettable area increasing to 24,000 sq m from 20,000 sq m, had an occupancy rate of 75%. The majority of tenants were service-based, consultants ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s ...

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization ...

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of ...